AMPH Stock Analysis: Amphastar P | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.078m USD | 12M Return: 6.6% | US03209R1032 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.2M
EPS Trend: -59.3%
Qual. Beats: 1
Rev. Trend: 75.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, operating primarily in the United States, China, and France. Founded in 1996 and headquartered in Rancho Cucamonga, California, the company has been public since its 2014 IPO.
The company markets a diverse portfolio spanning emergency care, hospital products, and chronic disease treatments, including BAQSIMI (nasal glucagon for severe hypoglycemia), Primatene MIST (epinephrine inhaler for asthma), Enoxaparin (low molecular weight heparin for thrombosis), and Naloxone products for opioid overdose. Its hospital and diagnostic offerings include Cortrosyn, Amphadase, Lidocaine formulations, Phytonadione injection, and prefilled emergency syringes, while respiratory and chronic-disease products include Albuterol, Ipratropium Bromide HFA, Iron sucrose, and Teriparatide. The company also produces active pharmaceutical ingredients such as Recombinant Human Insulin and porcine insulin API.
- BAQSIMI glucagon nasal spray revenue grows on diabetes prevalence
- Enoxaparin generic injectable margins face increased competition
- China and France international sales currency and regulatory risks
- Primatene MIST and inhalation aerosol demand seasonal variability
- FDA approval pipeline for new injectable and intranasal products
- Capital allocation through buybacks and R&D spending pressures margins
| Net Income: 78.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.82 > 1.0 |
| NWC/Revenue: 50.37% < 20% (prev 56.15%; Δ -5.77% < -1%) |
| CFO/TA 0.11 > 3% & CFO 184.6m > Net Income 78.5m |
| Net Debt (474.5m) to EBITDA (192.9m): 2.46 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.2m) vs 12m ago -8.11% < -2% |
| Gross Margin: 47.68% > 18% (prev 50.03%; Δ -2.34% > 0.5%) |
| Asset Turnover: 43.47% > 50% (prev 44.59%; Δ -1.13% > 0%) |
| Interest Coverage Ratio: 4.91 > 6 (EBIT TTM 128.1m / Interest Expense TTM 26.1m) |
| A: 0.21 (Total Current Assets 631.0m - Total Current Liabilities 263.2m) / Total Assets 1.74b |
| B: 0.40 (Retained Earnings 703.6m / Total Assets 1.74b) |
| C: 0.08 (EBIT TTM 128.1m / Avg Total Assets 1.68b) |
| D: 0.79 (Book Value of Equity 768.2m / Total Liabilities 975.6m) |
| Altman-Z'' = 4.04 = AA |
| DSRI: 1.06 (Receivables 144.9m/134.6m, Revenue 730.0m/720.3m) |
| GMI: 1.05 (GM 50.03% / 47.68%) |
| AQI: 0.99 (AQ_t 0.42 / AQ_t-1 0.42) |
| SGI: 1.01 (Revenue 730.0m / 720.3m) |
| TATA: -0.06 (NI 78.5m - CFO 184.6m) / TA 1.74b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at USD 26.62 with a total of 437,694 shares traded. Over the past week, the price has changed by +4.68%, over one month by +15.54%, over three months by +39.96% and over the past year by +6.61%.
Current recommended Stop Loss: 25.40 (which is 4.6% or 1.3 ATR below the current price).
Amphastar P has received a consensus analysts rating of 2.86. Therefore, it is recommended to hold AMPH.
- StrongBuy: 0
- Buy: 0
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 22.5 | -15.5% |
P/E Trailing = 15.0
P/S = 1.4771
P/B = 1.3833
P/EG = 2.77
Revenue TTM = 730.0m USD
EBIT TTM = 128.1m USD
EBITDA TTM = 192.9m USD
Long Term Debt = 609.6m USD (from longTermDebt, last quarter)
Short Term Debt = 11.3m USD (from shortTermDebt, last quarter)
Debt = 764.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 76.3m
Net Debt = 474.5m USD (calculated: Debt 764.6m - CCE 290.1m)
Enterprise Value = 1.55b USD (1.08b + Debt 764.6m - CCE 290.1m)
Interest Coverage Ratio = 4.91 (Ebit TTM 128.1m / Interest Expense TTM 26.1m)
EV/FCF = 10.16x (Enterprise Value 1.55b / FCF TTM 152.9m)
FCF Yield = 9.85% (FCF TTM 152.9m / Enterprise Value 1.55b)
FCF Margin = 20.94% (FCF TTM 152.9m / Revenue TTM 730.0m)
Net Margin = 10.76% (Net Income TTM 78.5m / Revenue TTM 730.0m)
Gross Margin = 47.68% ((Revenue TTM 730.0m - Cost of Revenue TTM 381.9m) / Revenue TTM)
Gross Margin QoQ = 50.83% (prev 41.08%)
Tobins Q-Ratio = 0.89 (Enterprise Value 1.55b / Total Assets 1.74b)
Interest Expense / Debt = 3.42% (Interest Expense 26.1m / Debt 764.6m)
Taxrate = 23.01% (23.5m / 102.0m)
NOPAT = 98.7m (EBIT 128.1m * (1 - 23.01%))
Current Ratio = 2.40 (Total Current Assets 631.0m / Total Current Liabilities 263.2m)
Debt / Equity = 1.00 (Debt 764.6m / totalStockholderEquity, last quarter 768.2m)
Debt / EBITDA = 2.46 (Net Debt 474.5m / EBITDA 192.9m)
Debt / FCF = 3.10 (Net Debt 474.5m / FCF TTM 152.9m)
Total Stockholder Equity = 776.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.68% (Net Income 78.5m / Total Assets 1.74b)
RoE = 10.11% (Net Income TTM 78.5m / Total Stockholder Equity 776.8m)
RoCE = 9.24% (EBIT 128.1m / Capital Employed (Equity 776.8m + L.T.Debt 609.6m))
RoIC = 6.78% (NOPAT 98.7m / Invested Capital 1.46b)
WACC = 6.21% (E(1.08b)/V(1.84b) * Re(8.75%) + D(764.6m)/V(1.84b) * Rd(3.42%) * (1-Tc(0.23)))
Discount Rate = 8.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.47 | Cagr: -7.74%
[DCF] Terminal Value 77.97% ; FCFF base≈136.6m ; Y1≈156.6m ; Y5≈230.5m
[DCF] Fair Price = 70.38 (EV 3.47b - Net Debt 474.5m = Equity 2.99b / Shares 42.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -59.33 | EPS CAGR: -8.09% | SUE: 1.63 | # QB: 1
Revenue Correlation: 75.36 | Revenue CAGR: 5.23% | SUE: 0.65 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.86 | Chg30d=+9.25% | Revisions=+30% | Analysts=7
EPS current Year (2026-12-31): EPS=2.97 | Chg30d=+16.22% | Revisions=+50% | GrowthEPS=-8.6% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=2.64 | Chg30d=+50.00% | Revisions=-25% | GrowthEPS=+21.7% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +39% (up=11, down=4)